Literature DB >> 31977476

Recurrent Immunoglobulin G4-Related Disease Shown on 18F-FDG and 68Ga-FAPI PET/CT.

Qingqing Pan, Yaping Luo, Wen Zhang1.   

Abstract

A 21-year-old man had been diagnosed with immunoglobulin G4-related disease (IgG4-RD) for 5 years, and the disease recurred 1 month ago. F-FDG PET/CT revealed intense FDG activity in the pituitary stalk, submandibular gland, pleura, pericardium, pancreas, liver, prostate, and multiple lymph nodes, which were considered the involvements of IgG4-RD. Ga-FAPI PET/CT also showed intense Ga-FAPI uptake in the above FDG-avid lesions except the lymph node involvement. Additionally, involvement in the lacrimal glands was detected by Ga-FAPI. The positive findings of Ga-FAPI in the current case highlighted that Ga-FAPI may have value in the evaluation of IgG4-RD.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31977476     DOI： 10.1097/RLU.0000000000002919

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  12 in total

1.  The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.

Authors:  Lianjun Lan; Hanxiang Liu; Yingwei Wang; Jia Deng; Dengsai Peng; Yue Feng; Li Wang; Yue Chen; Lin Qiu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-19       Impact factor: 9.236

2.  From Suspicion to Diagnosis: Analysis on the Clinical Characteristics of 37 Cases of IgG4-Related Disease (IgG4-RD) in Northeast China.

Authors:  Shanshan Zhang; Jun Zhang; Yifang Li; Jian Jiao
Journal:  J Inflamm Res       Date:  2022-08-06

Review 3.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

4.  Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas.

Authors:  Xiao Zhang; Wenyu Song; Chunxia Qin; Fang Liu; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-15       Impact factor: 9.236

Review 5.  Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.

Authors:  Paul Windisch; Daniel R Zwahlen; Stefan A Koerber; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal:  Cancers (Basel)       Date:  2020-09-15       Impact factor: 6.639

Review 6.  Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.

Authors:  Paul Windisch; Daniel R Zwahlen; Frederik L Giesel; Eberhard Scholz; Patrick Lugenbiel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal:  EJNMMI Res       Date:  2021-02-19       Impact factor: 3.138

7.  68Ga-FAPI-04 PET/MR is helpful in differential diagnosis of pancreatitis from pancreatic malignancy compared to 18F-FDG PET/CT: a case report.

Authors:  Yi Shou; Qiaoyi Xue; Jianmin Yuan; Jun Zhao
Journal:  Eur J Hybrid Imaging       Date:  2021-06-15

Review 8.  FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.

Authors:  Tianshuo Yang; Long Ma; Haodong Hou; Feng Gao; Weijing Tao
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244

9.  Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [18F]FDG PET/CT and MRI.

Authors:  Christian Linz; Roman C Brands; Olivia Kertels; Alexander Dierks; Joachim Brumberg; Elena Gerhard-Hartmann; Stefan Hartmann; Andreas Schirbel; Sebastian Serfling; Yingjun Zhi; Andreas K Buck; Alexander Kübler; Julian Hohm; Constantin Lapa; Malte Kircher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-29       Impact factor: 9.236

10.  68Ga-FAPI and 18F-FDG PET/CT Images in a Patient With Extrapulmonary Tuberculosis Mimicking Malignant Tumor.

Authors:  Bingxin Gu; Zhiguo Luo; Xinhong He; Jian Wang; Shaoli Song
Journal:  Clin Nucl Med       Date:  2020-11       Impact factor: 10.782
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.